Erschienen in:
01.06.2007 | Adis Profile Report
Selegiline Transdermal System in Major Depressive Disorder
Profile Report
verfasst von:
James E. Frampton, Greg L. Plosker
Erschienen in:
CNS Drugs
|
Ausgabe 6/2007
Einloggen, um Zugang zu erhalten
Excerpt
Major depressive disorder (MDD) is a highly prevalent and disabling condition.[
4] It has a lifetime prevalence of ≊16% in the US;[
5] worldwide, it is the leading cause of non-fatal disease burden (accounting for 12% of all years lived with disability) and the fourth leading cause of total disease burden (accounting for 4.4% of all disability-adjusted life-years).[
6] Treatment modalities include psychotherapy, pharmacotherapy, combined psychopharmacotherapy or electroconvulsive therapy. Of these, pharmacotherapy is the preferred choice for moderate-to-severe episodes of depression, about half of which will show improvement.[
7] …